Literature DB >> 10634423

Regulated expression and potential roles of p53 and Wilms' tumor suppressor gene (WT1) during follicular development in the human ovary.

A Makrigiannakis1, K Amin, G Coukos, J L Tilly, C Coutifaris.   

Abstract

It has been previously demonstrated that the gonadotropin-mediated inhibition ofapoptosis in rat ovarian granulosa cells is associated with changes in the expression of several cell death-regulatory genes, including p53. In addition, it has been shown that the actions of p53 may be amplified through a cooperative interaction with the Wilms' tumor suppressor gene product (WT1). Based on these findings, the present studies were conducted to determine whether p53 and WT1 are expressed and gonadotropin regulated in the human ovary and to study the relationship between tumor suppressor gene expression and apoptosis in human granulosa/lutein cells (GCs). Analysis of total RNA prepared from human GCs using the RT-PCR demonstrated the presence of p53 messenger RNA (mRNA) and four WT1 mRNA splice variants. These observations were supported by Northern blot analysis of total RNA prepared from human GCs, which revealed the presence of a single (approximately 2.8 kb) p53 mRNA transcript and two primary (approximately 1.8 and approximately 3.5 kb) WT1 mRNA transcripts. Western blot analysis of nuclear protein extracts from human GCs yielded one immunoreactive protein of the expected size (approximately 53 kDa) recognized by a p53 antibody and one immunoreactive protein of the expected size (approximately 52-54 kDa) recognized by the WT1 antibody. Immunohistochemical staining showed that both molecules were localized to nuclei of human GCs and were coordinately regulated during follicular development. Immunofluorescence analysis showed that p53 protein was localized exclusively to nuclei of GCs undergoing apoptosis during in vitro culture and was similarly localized to nuclei and cytoplasm of apoptotic granulosa cells in atretic follicles in vivo. To further evaluate whether human GC apoptosis is linked to increased expression of tumor suppressor genes, we analyzed levels of p53 and WT1 mRNA and protein in GCs induced to undergo apoptosis in vitro. Healthy (nonapoptotic) GCs snap-frozen immediately after isolation from patients undergoing in vitro fertilization-embryo transfer possessed relatively low, but detectable, levels of p53 and WT1 mRNA and protein. However, following serum-free culture to induce apoptosis, p53 mRNA and protein levels increased significantly after 24 h, paralleling the increase in the number of apoptotic GCs. The induction of both p53 mRNA and protein in GCs was inhibited by the addition of human CG to the culture medium. In contrast, WT1 mRNA and protein levels remained constitutive in GCs incubated for 24 h compared with GCs snap-frozen immediately after isolation. We conclude that the p53 and WT1 genes are expressed at the mRNA and protein levels in human GCs and that expression of p53 is regulated during follicular maturation. Nuclear accumulation of p53 protein occurs in human GCs during apoptosis in vitro and in vivo, and p53 mRNA and protein are up-regulated in GCs starved of hormonal support but down-regulated by the presence of human CG. We propose that the products of these two principal tumor suppressor genes serve as important regulators of human follicular development and corpus luteum function.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10634423     DOI: 10.1210/jcem.85.1.6246

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  8 in total

1.  The involvement of proliferation and apoptosis in the early human gonad development.

Authors:  T Vukusic Pusic; T Janjic; I Dujmovic; A Poljicanin; V Soljic; M Saraga-Babic; K Vukojevic
Journal:  J Mol Histol       Date:  2012-10-17       Impact factor: 2.611

2.  Luteogenic hormones act through a vascular endothelial growth factor-dependent mechanism to up-regulate alpha 5 beta 1 and alpha v beta 3 integrins, promoting the migration and survival of human luteinized granulosa cells.

Authors:  Alexandra Rolaki; George Coukos; Dimitris Loutradis; Horace M DeLisser; Christos Coutifaris; Antonis Makrigiannakis
Journal:  Am J Pathol       Date:  2007-05       Impact factor: 4.307

3.  Estimation of molecular upper remission limit for monitoring minimal residual disease in peripheral blood of acute myeloid leukemia patients by WT1 expression.

Authors:  Jaroslav Polák; Hana Hájková; Jacqueline Maalaufová-Soukupová; Jana Marková; Cyril Sálek; Jiří Schwarz; Cedrik Haškovec
Journal:  Exp Ther Med       Date:  2011-10-11       Impact factor: 2.447

4.  Effects of Prepubertal Exposure to Aroclor-1221 on Reproductive Development and Transcriptional Gene Expression in Female Rats.

Authors:  Xiang Hua; Huahua Jiang; Na Guo; Yaoyao Du; Xiaoqiong Yuan; Taoran Deng; Xuemei Teng; Yangcheng Yao; Yufeng Li
Journal:  Reprod Sci       Date:  2020-08-20       Impact factor: 3.060

Review 5.  Wilms tumor gene (WT1) expression as a panleukemic marker.

Authors:  Hans D Menssen; Jan M Siehl; Eckhard Thiel
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.490

6.  Loss of betaglycan contributes to the malignant properties of human granulosa tumor cells.

Authors:  Maree Bilandzic; Simon Chu; Paul G Farnworth; Craig Harrison; Peter Nicholls; Yao Wang; Ruth M Escalona; Peter J Fuller; Jock K Findlay; Kaye L Stenvers
Journal:  Mol Endocrinol       Date:  2009-01-22

7.  Aberrant granulosa cell-fate related to inactivated p53/Rb signaling contributes to granulosa cell tumors and to FOXL2 downregulation in the mouse ovary.

Authors:  Victoria Cluzet; Marie M Devillers; Florence Petit; Stéphanie Chauvin; Charlotte M François; Frank Giton; Catherine Genestie; Nathalie di Clemente; Joëlle Cohen-Tannoudji; Céline J Guigon
Journal:  Oncogene       Date:  2019-11-19       Impact factor: 9.867

8.  The new molecular biology of granulosa cell tumors of the ovary.

Authors:  Nicolas Kalfa; Reiner A Veitia; Bérénice A Benayoun; Brigitte Boizet-Bonhoure; Charles Sultan
Journal:  Genome Med       Date:  2009-08-25       Impact factor: 11.117

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.